Hormonal
GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce significant weight loss in individuals with obesity by suppressing appetite and reducing energy intake through central nervous system mechanisms.
GLP-1 receptor agonists like semaglutide and liraglutide are highly effective pharmacological interventions for obesity that work by targeting the biological drivers of weight gain, specifically by suppressing appetite and reducing energy intake. They are administered via injection (daily or weekly) and have shown substantial weight loss in clinical trials. For those who struggle with injections, oral alternatives are in development. While currently expensive and less accessible in some regions, they represent a significant advancement over lifestyle changes alone for managing obesity and its comorbidities.
liraglutide and semaglutide have demonstrated remarkable efficacy in clinical trials, leading to substantial weight reductions (Pi-Sunyer et al 2015; Wilding et al 2021) by suppressing appetite and reducing energy intake (Friedrichsen et al 2021)
Why this rating
The paper cites multiple large-scale randomized controlled trials (e.g., Pi-Sunyer 2015, Wilding 2021) and recognizes the work with a major clinical award.
Source
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Yu-Fei Zhou et al. · Current Medicine · 2024
DOI 10.1007/s44194-024-00041-w
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.Strong
- Multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 receptor agonists (orforglipron) are emerging treatments that reduce body weight and improve metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →